PhRMA And AAM Urge New Approaches In Dealing With COVID-19 Supply Chain Disruptions
As costs and delays mount, the brand and generic groups seek government solutions. AAM continues to press for federal contracts, and PhRMA wants the Department of Transportation to use its enforcement discretion under CARES Act to mandate international flights. AAM survey finds pandemic has caused 224% spike in the cost of transporting drugs.
You may also be interested in...
The pharmaceutical industry should use alternative transportation routes and have a business continuity plan for dealing with distribution center closures in light of the COVID-19 pandemic. They should also work closely with third-party logistics providers in ensuring drivers are complying PPE requirements.
In an attempt to strengthen the US generic drug supply chain and reduce dependence on certain countries for supply, the AAM has proposed a policy framework “blueprint” that requires government purchasing commitments in exchange for industry manufacturing expansion.
The association for manufacturers of generics and biologics calls for public sector investment in priority medicines.